Monitor the Phase 3 REGAL topline readout for GPS in AML expected this month, as the offering's dilutive impact is tied to the company's clinical catalyst. Watch for final prospectus supplement filing and closing on November 20, 2026.
Drugs in focus
SLS drug pipeline →galinpepimut-S
● Neutral Named in this press release- Impact
- Phase
- Phase 3
- Time to market
- If the Phase 3 REGAL trial succeeds, the earliest potential regulatory submission (BLA) would follow the topline readout in Q4 2026, with an FDA review timeline of roughly 10-12 months thereafter, putting a potential approval in late 2027 or early 2028 at the earliest.
- Next catalyst
- None dated
What to watchWatch for the topline Phase 3 REGAL overall survival readout, expected within the next two months (Q4 2026). A positive result showing statistically significant survival benefit could drive the stock toward analyst targets of $30-$35, while a miss or marginal result would likely devastate the stock given the company's pre-revenue status and dependence on this single asset. The ongoing securities investigation adds a secondary legal risk to monitor.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 19 $14.86entry
- T+1 · 2d ago −8.08%α −4.43% · $13.66
- T+5 · in 5d Pending
- T+20 · in 26d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
SELLAS priced its previously announced underwritten public offering of 11,538,462 common shares at $13.00 per share, with gross proceeds expected at $150.0 million, plus a 30-day underwriter option for up to 1,730,769 additional shares. The offering, expected to close November 20, 2026, follows the company's positive Phase 3 REGAL trial data for GPS in AML and is dilutive to existing shareholders.
Key Financial Metrics
Key Facts
- Priced 11,538,462 shares at $13.00 per share
- Gross proceeds expected to be $150.0 million
- 30-day underwriter option for up to 1,730,769 additional shares
- Offering expected to close November 20, 2026
- J.P. Morgan and TD Cowen are lead book-running managers; Mizuho also book-running; A.G.P./Alliance Global Partners and Maxim Group are lead managers
- Offering made pursuant to shelf registration statement on Form S-3 (File No. 333-294504)
- Company reported Q3 2026 net loss of $10.1M ($0.05 per share) and cash of $134.7M on November 12, 2026
- Positive Phase 3 REGAL trial data for GPS in AML announced
Financial Impact
$150.0 million gross proceeds from 11,538,462 shares at $13.00 per share; potential additional shares under 30-day option
Risk Factors
- Dilution to existing shareholders from the offering
- Underwriter option could add up to 1,730,769 additional shares
- Clinical trial and regulatory approval uncertainties for GPS and SLS009
- Market conditions and customary closing conditions could affect offering completion
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3406277 |
Track record
19 reports on SLS
3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +63.62% at T+60 after the Mar 12, 2026 report. 3 of 5 went positive at some point.
Filters
- Nov 20, 20262d ago 8-K Bearish 6/10 Entry $14.80 Now $13.66 +7.70% settles Nov 23
- Nov 19, 20262d ago 424B5 Bearish 6/10 Entry $14.86 Now $13.66 +8.08% settles Nov 23
- Nov 18, 20263d ago Press Release Bearish 6/10 Viewing Entry $14.86 to $13.66 Now $13.66 +8.08% ▲ +8.08% +4.43% vs SPY
- Nov 17, 20264d ago 424B5 Bearish 6/10 Entry $17.95 to $14.86 Now $13.66 +23.90% ▲ +17.21% +15.25% vs SPY
- Nov 17, 20264d ago Press Release Bearish 6/10 Entry $17.95 to $14.86 Now $13.66 +23.90% ▲ +17.21% +15.25% vs SPY
- Nov 17, 20265d ago 8-K Bullish 7/10 Entry $19.15 to $17.95 Now $13.66 −28.67% ▼ −6.27% −5.96% vs SPY
- Nov 17, 20265d ago Press Release Bullish 8/10 Entry $19.15 to $17.95 Now $13.66 −28.67% ▼ −6.27% −5.96% vs SPY
- Nov 12, 20269d ago 8-K Neutral 5/10 Entry $7.86 to $7.47 Now $13.66 +73.79% ▼ −4.96% −3.05% vs SPY
- Nov 10, 202611d ago SC 13G Neutral 3/10 Entry $8.37 to $8.42 Now $13.66 +63.20% ▲ +0.60% −0.72% vs SPY
- Nov 3, 202618d ago Institutional Cluster Neutral 3/10 Entry $8.87 to $9.14 Now $13.66 +54.00% ▲ +3.04% +1.39% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers